Full Press Release Details
LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024 , in Cairns, Australia.
Details of the presentation are as follows:
| Title: | Advancing Bacteriophage Therapy from Discovery to Clinical Trials |
| Session: | Phage Therapy Session 2 – Clinical Application |
| Presenter: | Steven Branston, Australia Site Head |
| Day: | Thursday, July 18 |
| Time: | 11:20am-11:40am AEST (9:20pm-9:40pm EDT on Wednesday, July 17) |
| For more information: https://www.vom2024.org/ |
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa , Staphylococcus aureus , and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
At Armata: Pierre Kyme Armata Pharmaceuticals, Inc. [email protected] 310-665-2928
Investor Relations: Joyce Allaire LifeSci Advisors, LLC [email protected] 212-915-2569
SOURCE Armata Pharmaceuticals, Inc.